← Mechanisms of action
Clostridium difficile
ORGANISMPeptoclostridium difficile
Drugs acting on this target (14)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| c. difficile toxoid vaccine | Immunity, active | experimental | Vaccine | Clostridium difficile immunity, active |
| cdvax | Immunity, active | experimental | Vaccine | Clostridium difficile immunity, active |
| clostridium difficile toxoids a and b | Immunity, active | experimental | Vaccine | Clostridium difficile immunity, active |
| gsk2904545a | Immunity, active | experimental | Vaccine | Clostridium difficile immunity, active |
| ic84 | Immunity, active | experimental | Vaccine | Clostridium difficile immunity, active |
| vla84 | Immunity, active | experimental | Vaccine | Clostridium difficile immunity, active |
| actoxumab | Immunity, passive | experimental | mAb | Clostridium difficile immunity, passive |
| bezlotoxumab (zinplava) | Immunity, passive | approved | mAb | Clostridium difficile immunity, passive |
| Chicken egg-derived anti-C.difficile polyclonal antibodies | Immunity, passive | experimental | Animal product | Clostridium difficile immunity, passive |
| lmn-401 | Immunity, passive | experimental | Biological | Clostridium difficile immunity, passive |
| art24 | Inhibitor | experimental | Cell therapy | Clostridium difficile inhibitor |
| rec-3964 | Inhibitor | experimental | Small molecule | Clostridium difficile inhibitor |
| tolevamer | Inhibitor | experimental | Small molecule | Clostridium difficile inhibitor |
| vp20621 | Supplementation | experimental | Cell therapy | Clostridium difficile supplementation |